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Summary--The LNCaP-FGC (fast growing colony) cell line, a subline derived from the 
LNCaP cell line, shares all the main characteristics, including its androgen sensitivity, 
described for the parental line. A number of sublines originating from the FGC line were 
characterized with respect o their response to steroid-depleted medium and to the synthetic 
androgen R1881. The growth of FGC cells in DCC medium with 0.1 nM R1881 was 
stimulated 2-3-fold compared to growth in DCC medium only. FGC cells that were 
continuously grown in DCC medium did not die, but their growth rate was clearly slowed 
down, and the cells remained responsive to androgen. These cells, therefore, have the 
androgen-sensitive, rather than the androgen-dependent phenotype. As cells of the subline 
FGC-JB could not be maintained in DCC medium, these cells better epresent the androgen- 
dependent cell type. In contrast o the FGC line, cells of the R line, grew equally well in 
medium with complete or DCC serum. Under none of these culture conditions, R cells could 
significantly be stimulated further with R1881. Further analysis of the LNCaP-FGC sublines 
should provide valuable information concerning the development of androgen resistance in 
human prostate cancer. 
INTRODUCTION 
The origin of prostatic tumors is assumed to be 
monoclonal [1], but during tumor growth and 
progression, a diversity arises among the tumor 
cells [2]. This process is accompanied by a pro- 
gression from a steroid-sensitive to steroid- 
insensitive state[3]. This presents a major 
problem in the clinical management of prostate 
cancer, because tumors can only effectively be 
treated with endocrine therapy while they re- 
main androgen-sensitive [4, 5]. Studies with 
models for human breast cancer have shown 
that growth factors are involved in steroid regu- 
lation of breast cancer cell growth by both 
autocrine and paracrine mechanisms [6]. Steroid 
independence could result from uncoupled 
growth factor regulation by either constitutive 
secretion of a stimulatory factor or decreased 
secretion of an inhibitory factor [7]. 
A strong parallelism between androgen- 
related prostate and estrogen-regulated breast 
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cancer cell growth is very likely. The available 
information on androgen-mediated growth 
factor involvement in prostate cancer cell 
growth, however, is limited and is especially 
hampered by the lack of suitable model systems. 
Among the small number of permanent in vitro 
cell lines of human prostate cancer described 
up to now, the LNCaP (lymphe node carci- 
noma of the prostate) cell line, developed by 
Horoszewicz [8], is the only model with andro- 
gen responsive growth in vitro [9]. LNCaP cells 
secrete prostatic acid phosphatase and prostate 
specific antigen, the cells contain considerable 
amounts of androgen receptors, whereas 
estrogen and progesterone receptors are not 
detectable [10]. 
During the last few years, the LNCaP model 
has gained much interest. The LNCaP-FGC 
line, which is derived from an ~arly passage of 
the original culture, has been distributed from 
the Roswell Park Memorial Institute over a 
large number of institutes, and it is also avail- 
able through the American Type Culture Col- 
lection. This subline differs from the parental 
cell line (9) only by its growth rate. The LNCaP 
cells are shown to secrete polypeptide growth 
factors, such as epidermal growth factor (EGF) 
and transforming rowth factor (TGF)-ct [11] 
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and, like androgens, EGF has been demon- 
strated to stimulate growth of the LNCaP 
cells [12]. The growth regulation of LNCaP cell 
by androgens and growth factors has been 
reviewed by Schuurmans et al. in a separate 
paper in this publication [13]. 
Propagation of LNCaP cell cultures led to the 
development of a number of sublines with 
different patterns of hormonal responsiveness. 
These sublines descended from the parental 
LNCaP line either spontaneously or by main- 
tainance of the original cell line in medium with 
steroid-depleted serum. An example is the spon- 
taneously emerged, androgen-insensitive LN- 
CaP-r (resistant) subline, which was developed 
and further characterized by Hasenson et 
al. [14]. The present contribution describes the 
derivation and the major properties of the 
LNCaP sublines and some of the recent results 
obtained at our laboratory. 
EXPERIMENTAL 
Cell lines 
The LNCaP cell line was derived from culture 
explants of needle biopsy material from a 
lymphe node metastases of a prostate cancer 
patient [8]. The arisen cultures could only be 
maintained by passing colonies of cells using 
the technique of microtransplantation over a 
period in excess of one year. These cultures 
ultimately resulted in a cell line, LNCaP, 
resembling a conventional cell culture, i.e. a 
line with a constant growth rate that could 
be subcultivated by enzymatic dispersion, 
as described in more detail by Horoszewicz 
et al. [8]. 
Figure 1 shows a schematic representation f 
the LNCaP cell line and its derived sublines as 
discussed in the present paper. The scheme also 
contains information on the current knowledge 
of the various sublines with respect to their 
androgen responsiveness. The LNCaP-FGC cell 
line descended from a fast growing colony of the 
original LNCaP cultures, and thus is considered 
the reference LNCaP cell line. The FGC line 
was kindly made available to us by Dr Julius 
Horoszewicz (Buffalo, U.S.A.) and was trans- 
ferred to our laboratory as a 16th passage 
culture. 
The FGC-JB is a derivative of an early pas- 
sage culture of the FGC. The LNO subline, also 
a gift from Dr Julius Horoszewicz, originated 
from cultures of an early (rth) passage of the 
parental line that was grown and subsequently 
maintained in medium with steroid-depleted 
serum (Horoszewicz; personal communication). 
The LNCaP-r subline (designated 'R' in 
our laboratory), was kindly provided by Dr 
Hasenson (Huddinge, Sweden). 
Cell culture 
The cell lines FGC, FGC-JB and R were 
routinely maintained as monolayer cultures in 
RPMI medium (Gibco Europe, Breda, The 
Netherlands) supplemented with 10% fetal 
bovine serum (FBS; Boehringer, Mannheim, 
Fed. Rep. Germany, or Hyclone, Greiner, 
Alphen a/d Rijn, The Netherlands), 2 mM glu- 
tamine and antibiotics. The LNO cultures were 
grown under the same conditions, except hat 
the medium contained 5% dextran-coated char- 
coal (DCC; dextran 0.1%, charcoal 1%)-treated 
(i.e. steroid-depleted) serum. Untreated (FBS) 
serum contained 0.5-1.0 nM of testosterone (T), 
whereas in DCC serum less than 0.1 nM of T 
(the detection limit of the assay) was estimated. 
All cell cultures were grown in plastic tissue 
culture flasks (Falcon, Oxnard, U.S.A.). Cul- 
tures were kept in a humidified atmosphere of
5% CO 2 in air, at a temperature of 37°C. Cells 
in vitro 
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Fig. 1. Schematic representation f the LNCaP cell line and its descending sublines. EM: electron 
microscopically studied subline (cf. Ref. [8]); LNO: lymphe node original; FGC: fast growing colony; 
FGC-JB: FGC derivative; R (=LNCaP-r): LNCaP-(androgen)-resistant (cf. Ref. [14]). 
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were subcultivated at weekly intervals using a 
mixture of 0.05% trypsin and 0.01% EDTA. 
Cell growth experiments 
The growth of the different cell lines under 
standard conditions, i.e. in medium with 10% 
FBS, was compared with their behavior when 
FBS was replaced by DCC serum. More specifi- 
cally, the androgen responsiveness of the vari- 
ous cell types was determined with the synthetic, 
nonmetabolizable[15] androgen R1881 (New 
England Nuclear, Boston, MA, U.S.A.). Cells 
from stock cultures were plated at a density of 
5.105/25 cm 2 flask and grown for 2 or 3 days in 
5 ml medium with DCC serum, whereafter the 
medium was replaced by medium containing DCC 
serum and R1881 in the range of 10-7-10 -1~ M. 
Control cultures were grown in medium with 
0.01% ethanol vehicle. Media were changed 
every other day. Cells were harvested at 5, 6 or 
8 days (see Results section) after the androgen 
was added and counted using a hemocytometer. 
In some experiments he effects of DCC and 
R1881 treatment were evaluated with a test 
system based on the enzymatic reduction of the 
tetrazolium salt MTT [3-(4,5-dimethylthiazol-2- 
yl)-2,5-diphenyl-tetrazoliumbromide] [16]. This 
proliferation assay was previously described to 
be suitable for the assessment of hormone- 
stimulated growth of the LNCaP cell line [17]. 
After 3 days preincubation i  DCC medium, 
cells were harvested, seeded in microtiter plates 
(Costar, Cambridge, MA, U.S.A.) at a concen- 
tration of 5000 per well, and reincubated for 
24 h to allow for reattachment. Subsequently, 
the cells were exposed to experimental media for 
5 days. Cells were pulsed with MTT, incubated 
for 4 h whereafter the plates were processed as 
described by Romijn et al. [17]. 
RESULTS 
Effect of steroid-depleted serum on LNCaP 
growth 
Cultures of FGC and LNO differ in their 
response to medium supplemented with either 
FBS or DCC serum, as illustrated in Fig. 2. 
Both types of cells were cultured in medium 
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Fig. 2. Growth of FGC and LNO cells in complete (FBS) and in steroid-depleted (DCC) serum 
= medium change. 
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with a serum percentage in which the respective 
cells were routinely propagated (see Experimen- 
tal section). No difference was observed between 
the growth of the FGC cell in medium sup- 
plemented with 10 or 5% (FBS) serum (result 
not shown). After a lag phase of 2 days, FGC 
cells exponentially grew for the next 5 days, the 
doubling time being 34 h, whereas during the 
same period of time in DCC medium the cells 
doubled only once (Fig. 2). 
FGC cells that were continued to grow in 
DCC medium did not die, but clearly slowed 
down their growth rate, while the cells also 
showed morphological changes. Such cultures 
could be maintained for long periods of time 
and therefore were considered as being a separ- 
ate LNCaP subline, designated FGC-DCC. 
Androgen responsiveness of the FGC line 
The ability of androgens (i.e. R1881) to 
stimulate growth of the FGC cells in the pres- 
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ence of 5% DCC serum is shown in Fig. 3A. 
FGC cultures were preconditioned for 3 days by 
growing the cells in medium with 5% DCC- 
medium prior to harvesting and seeding the cells 
in microtiter plates for performing an MTT 
assay. Cells that were continued to grow for 5 
days in DCC medium showed a 2.3-fold in- 
crease in cell number, and could be further 
stimulated with R1881 (Fig. 3). In this particu- 
lar experiment growth of FGC cells could sig- 
nificantly be stimulated (2.5-fold) only with a 
concentration of 0.1nM R1881, the level 
reached being similar to that of cells grown in 
control (FBS) serum. 
FGC-DCC cells cultured for 3 months (i.e. 
13 passages) in DCC medium were still sensitive 
for R1881, the pattern of response, however, 
was different from that of the parental FGC 
cells (cf. Fig. 3A and B). FGC-DCC cells were 
4-fold stimulated after prolonged growth in 
DCC medium, and were maximally (2-fold) 
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Fig. 3. MTT assay for dose response for FGC (A) and FGC-DCC (B) cells grown in complete (FBS) 
or steroid-depleted (DCC) medium, substituted with different concentrations of the synthetic androgen 
R1881. 
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stimulated at concentrations of 0.1-100nM 
R1881, whereas the response pattern of the 
parental FGC cell clearly showed an optimum 
at 0.1 nM. 
Growth properties of the FGC-JB subline 
The FGC-derived subline, FGC-JB, although 
like the parent FGC line androgen-sensitive, 
exhibited a slightly different pattern of respon- 
siveness (Fig. 4). Generally, growth of FGC-JB 
cell was less optimal: in comparison with the 
FGC line, JB cells detach more easily from the 
culture plastic and these cells had a slower 
growth rate. In contrast to the FGC cells (Fig. 4, 
left panel), neither during a 3-day period of 
preconditioning the JB cells, nor during the 
subsequent 6 days of culturing these cells in 
DCC medium, could any increase of the cell 
number be found (Fig. 4, right panel). Indepen- 
dent of the baseline (no steroid) response to the 
DCC medium, for both the FGC and the FGC- 
JB subline an approx. 2-fold increase of the cell 
number was obtained with 0.1 nM R1881. 
Growth properties of the LNCaP-r (R) line 
Figure 5 shows the result of an experiment 
(based upon an MTT assay) in which the re- 
sponsiveness of the FGC and the R line were 
compared. Growth of both the FGC and R line 
was stimulated when grown in DCC medium 
(3.2- and 4.5-fold, respectively). In contrast o 
the FGC cells, however, the R cells could not 
significantly be stimulated further by DCC 
medium with R1881 (0.1 nM), or by medium 
containing normal serum (FBS) (Fig. 5B). In 
fact, the R cells could be grown equally well in 
medium with either DCC, DCC + R1881, or 
FBS. In this experiment it was also proven that 
neither the FGC cell, nor the R cell when grown 
in FBS containing medium, could be further 
stimulated with the optimal concentration 
(0.1 nM) of R1881 (Fig. 5A and B). 
DISCUSSION 
There has always been a need for the develop- 
ment of hormone responsive model systems for 
human prostate cancer. Examples of hormone 
dependent human prostate carcinoma invivo are 
the transplantable PC-82, PC-EW and Honda 
tumors, as reviewed in Ref. [18]. These well 
characterized tumors were hetero-transplanted 
directly into nude mice, but lack the property of 
continuous growth in vitro. Up to now, LNCaP 
is the only androgen-dependent prostatic ell 
line established in vitro. Hence, it offers the 
possibility to study the involvement of (steroid) 
hormones and other factors in growth and 
differentiation of prostatic ancer cells under 
culture conditions. 
The FGC line, which directly descended from 
the LNCaP cell line, that was initially developed 
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Fig. 4. Androgen responsiveness of the FGC and the FGC-JB cells in the presence of  medium with or 
without 10 - t °M R1881. 
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from the patient material (Fig. 1), retained 
all the main properties of the original 
LNCaP [8, 9]. This cell line, which was dis- 
tributed over a large number of institutes, is the 
subject of an increasing number of different 
studies. Meanwhile, a number of sublines have 
been developed which either arose spon- 
taneously from the parental line, or which were 
obtained by prolonged culturing of the FGC 
line in steroid-depleted medium. Generally, the 
application of LNCaP and its derived sublines 
should be preceded by their careful characteriz- 
ation, in particular with respect o their hor- 
mone-dependent growth. It is recommended to
carefully assess the appropriate culture con- 
ditions, especially when FGC cells are trans- 
ferred from one laboratory to the other. 
Successful propagation of LNCaP cells strongly 
depends upon the culture conditions, such as the 
serum (batch) used, the type of culture plastic 
and the enzyme(s) used to subcultivate he cells, 
moreover, the cells appeared to be rather 
susceptible to mechanical disruption. 
The present contribution describes the origin 
of the LNCaP subline, LNO and of the 
FGC sublines, FGC-JB, FGC-DCC and R (cf. 
Fig. 1). Except for the FGC-DCC line, the 
LNCaP-derived sublines of the present study 
were previously studied by K6nig et al. [19] with 
respect to their cytogenetical characteristics. 
Clearly, the basic karyotype of the parental 
LNCaP cell line [20] was well preserved, which 
means that all sublines howed the same kary- 
otypic evolutionary pattern. This comprises a
doubling of the stem line to a near-tetraploid 
cell population, preservation of the original 
markers, and generation of some new, subline 
specific marker chromosomes [19]. 
The growth behavior of all LNCaP sublines 
was studied in steroid-depleted (DCC) and in 
androgen-substituted medium, the results being 
summarized in Table 1. FGC-JB appeared to be 
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Fig. 5. MTT assay for growth of FGC cells (upper panel) and R cells (lower panel) in complete (FBS) 
and (DCC) medium with and without the synthetic androgen R1881. 
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Table 1. Growth properties of several sublines of the LNCaP in vitro 
model 
Growth 
Subline FBS FBS-DCC 
Response to 
androgen 
(R1881) 
FGC + + + + + 
FGC-DCC + + + + + 
FGC-JB + - -  + 
LNO + + + + ND 
R ++ ++ - -  
FBS: Fetal bovine serum; DCC: dextran-coated charcoal treated 
serum; ND: not determined. 
- -  = no growth; + = growth; + + = faster growth. 
the only line that can not permanently bemain- 
tained in medium with DCC serum (Fig. 4). 
Long-term cultures (up to 6 months) of FGC 
cells in DCC medium i.e. in the absence of 
androgens, did not result in growth of andro- 
gen-independent cells, although compared to 
the FGC line, the FGC-DCC cells showed a 
slightly different pattern of androgen (R1881) 
responsiveness (Fig. 3). Apparently, under these 
conditions the hormone-dependent phenotype 
of this cell line is rather stable. For more 
conclusive results, however, growth of the cells 
under these circumstances should be followed 
for longer periods of time. Moreover, it was 
observed that FGC cells cultured in medium 
with complete (FBS) serum for more than 30 
passages gradually showed a better growth re- 
sponse in DCC medium (result not shown). A 
comparison between the growth of the parental 
FGC line and the R line showed a similar 
pattern of serum and androgen responsiveness 
(Fig. 5). With that respect, it can not be ex- 
cluded that, finally, the R line arose from a 
long-term culture of the FGC line [14]. It can be 
concluded that under the condition of long-term 
maintainance of the FGC cells, an increase of 
the basal growth rate without steroid, rather 
than a reduced androgen-responsiveness was 
observed. Similar observations were made 
with estrogen-dependent ZR-75-1 and T-47-D 
human breast cancer cells [21]. 
A maximal growth response of all sublines 
tested was found for cultures in FBS medium 
(Figs 3 and 5, Table I). This could not be further 
enhanced by adding an optimal concentration 
of 0.1 nM R1881 to these cultures. With this 
respect care should be taken with the interpret- 
ation of results obtained with LNCaP cells 
tested for androgen responsiveness in the pres- 
ence of complete (i.e. androgen containing) 
serum, such as described for the R line by 
Hasenson et al. [14]. Such an approach can 
easily lead to misinterpretation f the results 
obtained. In the present study LNCaP cells were 
cultured for at least 3 days in DCC medium 
prior to testing their serum or androgen 
responsiveness. Although in some studies dihy- 
drotestosterone (DHT) was shown to be stimu- 
latory for LNCaP cells [11], care should also be 
taken for the application of this androgen, as it 
was previously shown by Berns et al. [22] that 
both testosterone (T) and DHT were rapidly 
metabolized by LNCaP cells. Therefore, in the 
present study the non-metabolizable androgen 
R1881[14] was used for testing androgen 
responsiveness of the LNCaP sublines. 
Steroid-depleted (DCC) serum has exten- 
sively been used in studies on cell growth and 
response of hormone-sensitive celllines [23, 24]. 
Although essential for preconditioning the 
LNCaP cells in hormone-sensitivity tests of the 
present study, the use of charcoal-treated serum 
is of limited value as it is not only depleted of 
steroids, but most likely also of growth factors 
and lipoproteins. Hence, there is a great need 
for the development of serum-free methods of 
culturing the LNCaP cells, such as described for 
other prostate cell lines by Kaighn et al. [25]. 
For a better and more reliable determination f 
the effects of hormones and growth factors on 
LNCaP growth in vitro, the use of defined media 
is a obligatory step in further studies with the 
LNCaP model. From our own experience and 
from other investigations [11] it became clear 
that at least for attachment to the plastic of the 
culture dish, LNCaP cells should necessarily be 
cultured for 24h in serum supplemented 
medium. Once attached, LNCaP cells could be 
tested for androgen and growth factor respon- 
siveness in a serum-free culture medium Ill]. 
In conclusion, the LNCaP cell line and its 
derived sublines provide a suitable in vitro 
model for the study of several aspects of andro- 
gen responsiveness in human prostate cancer. 
Investigations into the role of growth factors 
and their receptors, will further elucidate the 
mechanism of androgen stimulated growth of 
LNCaP cells. Comparative studies, including 
detailed cytogenetical characterization f the 
various sublines, should yield valuable infor- 
mation concerning the development of andro- 
gen resistance in human prostate cancer. 
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